SCHEMBL10066096

SCHEMBL10066096

N#[14C]Cc1ccc2c(c1)OC(F)(F)O2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.41
FAAH O00519 5/20 0.40
CTNNB1 P35222 3/20 0.40
WNT3A P56704 3/20 0.40
NOTUM Q6P988 1/20 0.39
SLC6A4 P31645 1/20 0.37
CYP2D6 P10635 2/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
DRD4 P21917 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CG P48736 1/20 0.36
KIF11 P52732 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
ROCK2 O75116 1/20 0.34
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ADORA3 P0DMS8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2537768 0.79 CYP19A1 (0.43) CYP19A1FAAHCTNNB1WNT3ANOTUM
SCHEMBL351795 0.77 CTNNB1 (0.45) CYP19A1FAAHCTNNB1WNT3ANOTUM
SCHEMBL350052 0.77 CTNNB1 (0.41) CYP19A1FAAHCTNNB1WNT3ANOTUM
SCHEMBL22657885 0.77 FAAH (0.45) CYP19A1FAAHCTNNB1WNT3ANOTUM
SCHEMBL2663369 0.77 CTNNB1 (0.41) CYP19A1FAAHCTNNB1WNT3ANOTUM
SCHEMBL351790 0.76 CTNNB1 (0.39) CYP19A1FAAHCTNNB1WNT3ANOTUM
SCHEMBL22657573 0.76 CTNNB1 (0.41) CYP19A1FAAHCTNNB1WNT3ANOTUM
SCHEMBL8367478 0.74 CNR1 (0.40) CYP19A1FAAHCTNNB1WNT3ANOTUM
SCHEMBL22657669 0.74 CTNNB1 (0.43) CYP19A1FAAHCTNNB1WNT3ASLC6A4
Hydrochloric Acid SCHEMBL4511238 0.73 TAAR1 (0.51) CYP19A1FAAHCTNNB1WNT3ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130274477-A1 PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-10-17 US disclosed
US-8461342-B2 Processes for producing cycloalkylcarboxamido-pyridine benzoic acids VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-11 US disclosed
US-20120203006-A1 PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-09 US disclosed
US-8124781-B2 Processes for producing cycloalkylcarboxamido-pyridine benzoic acids VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-28 US disclosed
US-20100036130-A1 PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-02-11 US disclosed
US-20090176989-A1 PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS VERTEX PHARMACEUTICALS INCORPORATED 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274477-A1 PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS DDC, PCCA, KMO CYP19A1 1098/4885FAAH 259/4885CTNNB1 3773/4885
US-20120203006-A1 PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS DDC, PCCA, KMO CYP19A1 1098/4885FAAH 259/4885CTNNB1 3773/4885
US-20090176989-A1 PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS DDC, PCCA, KMO CYP19A1 1098/4885FAAH 259/4885CTNNB1 3773/4885
US-20100036130-A1 PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS DDC, PCCA, KMO CYP19A1 1098/4885FAAH 259/4885CTNNB1 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.